interesting readings on Alzheimer and P53 used as a diagnostic biomarker
- Biogen’s Aducanumab might work for early stage Alzheiemer
- Zetterberg H and Burnham SC
"Blood-based molecular biomarkers for Alzheimer’s disease" Mol Brain 12.26 (2019) - Sabapathy, Kanaga, and David P. Lane.
"Understanding p53 functions through p53 antibodies." Journal of molecular cell biology 11.4 (2019): 317-329. - Jembrek MJ, et al.
"The interactions of p53 with tau and Aß as potential therapeutic targets for Alzheimer’s disease." Progress in neurobiology 168 (2018): 104-127. - Arce-Varas, Memo M, Uberti D, et al.
"Comparison of extracellular and intracellular blood compartments highlights redox alterations in Alzheimer's and mild cognitive impairment patients." Current Alzheimer Research 14.1 (2017): 112-122. - Buizza L, Memo M, Uberti D, et al.
"Conformational altered p53 affects neuronal function: relevance for the response to toxic insult and growth-associated protein 43 expression." Cell death & disease 4.2 (2013): e484. - Buizza L, Memo M, Uberti D, et al.
"Conformational altered p53 as an early marker of oxidative stress in Alzheimer's disease." PLoS One 7.1 (2012): e29789. - Lanni C, Memo M, Uberti D, et al.
"p53 at the crossroads between cancer and neurodegeneration." Free Radical Biology and Medicine 52.9 (2012): 1727-1733. - Lanni C, Memo M, Uberti D, et al.
"Unfolded p53 in blood as a predictive signature signature of the transition from mild cognitive impairment to Alzheimer's disease." Journal of Alzheimer's Disease 20.1 (2010): 97-104. - Lanni C, Memo M, Uberti D, et al.
"Conformationally altered p53: a novel Alzheimer's disease marker?." Molecular psychiatry 13.6 (2008): 641. - Uberti D, Memo M, et al.
"Identification of a mutant-like conformation of p53 in fibroblasts from sporadic Alzheimer's disease patients." Neurobiology of aging 27.9 (2006): 1193-1201.